title: Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats.
abstract: Over the past few decades, several bone-seeking radiopharmaceuticals including various bisphosphonate ligands and β-emitting radionuclides have been developed for bone pain palliation. Recently, (177)Lu was successfully labeled with zoledronic acid ((177)Lu-ZLD) as a new generation potential bisphosphonate and demonstrated significant accumulation in bone tissue. In this work, the absorbed dose to each organ of human for (177)Lu-ZLD and (177)Lu-ethylenediaminetetramethylene phosphonic acid ((177)Lu-EDTMP;as the only clinically bone pain palliation agent) was investigated based on biodistribution data in rats by medical internal radiation dosimetry (MIRD) method. (177)Lu-ZLD and (177)Lu-EDTMP were prepared in high radiochemical purity (>99%, instant thin layer chromatography (ITLC)) at the optimized condition. The biodistribution of the complexes demonstrated fast blood clearance and major accumulation in the bone tissue. The highest absorbed dose for both (177)Lu-ZLD and (177)Lu-EDTMP is observed in trabecular bone surface with 12.173 and 10.019 mSv/MBq, respectively. The results showed that (177)Lu-ZLD has better characteristics compared to (177)Lu-EDTMP and can be a good candidate for bone pain palliation.
authors.affiliation: Radiopharmaceutical Research and Development Lab (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
authors.forename: Hassan
authors.initials: H
authors.lastname: Yousefnia
authors.affiliation: Radiopharmaceutical Research and Development Lab (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
authors.forename: Samaneh
authors.initials: S
authors.lastname: Zolghadri
authors.affiliation: Radiopharmaceutical Research and Development Lab (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
authors.forename: Amir Reza
authors.initials: AR
authors.lastname: Jalilian
keywords: 177Lu; EDTMP; absorbed dose; biodistribution; zoledronate